drugset / Trial / NCT02120976

Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Oral Doses of JTT-252

NCT02120976 ↗

Phase 1 Terminated 85 enrolled Akros Pharma Inc.
RandomizedParallel-groupSingle-blindTreatment

Summary

The purpose of this study is to evaluate the safety, tolerability, and PK of single oral doses of JTT-252 and the effect of food on the PK of JTT-252 in healthy subjects, and to evaluate the safety, tolerability, PK and PD of single oral doses of JTT-252 in type 2 diabetes mellitus subjects.

Timeline

Start
2014-04
Primary completion
2015-02
Completion
2015-03

Drugs

EvaluationDrugModalityDoseRoute
Subject JTT-252 Unknown — Oral

Indications